الفهرس 
Pharmaceutical study on certain intranasal drug delivery systems using model drug
List of ContentsOnly 14 pages are availabe for public view
 |  | from | 316 |  |  |
| | | from | 316 | | |
Abstract
Betahistine dihydrochloride is indicated for the treatment of vertigo, tinnitus, hearing loss and nausea associated with Ménière’s syndrome. Betahistine dihydrochloride is generally given by oral route tablets 16 mg and 24 mg. A mild gastric complaints (e.g. vomiting, gastrointestinal pain, abdominal distension and bloating), have been observed. However, a substantial proportion of patients suffer severe nausea or vomiting during their vertigo attack, which may make oral treatment unsatisfactory. Moreover, betahistine dihydrochloride is highly metabolized primarily by the liver (SERC® product monograph - abbott., 2013). The aim of work in this thesis was to formulate betahistine dihydrochloride in certain nasal dosage forms to provide an alternative dosageforms in order to overcome the drug gastrointestinal disturbance side effects and bypass the liver first pass metabolic effect. The work in this thesis is divided into three chapters namely: Chapter I: Formulation and evaluation of betahistine dihydrochloride nasal Gel delivery system. Chapter II: Formulation and evaluation of betahistine dihydrochloride freeze - dried nasal Insert delivery system. Chapter III: Stability study of selected Formulations of betahistine dihydrochloride nasal Gel and Insert delivery systems